Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site

Summary The activation of the immune system for a selective removal of tumor cells represents an attractive strategy for the treatment of metastatic malignancies, which cannot be cured by existing methodologies. In this review, we examine the design and therapeutic potential of immunocytokines and b...

Full description

Saved in:
Bibliographic Details
Published in:Immunological reviews 2016-03, Vol.270 (1), p.178-192
Main Authors: Kiefer, Jonathan D., Neri, Dario
Format: Article
Language:English
Subjects:
Animals
Antibodies, Bispecific - chemistry
Antibodies, Bispecific - genetics
Antibodies, Bispecific - immunology
Antibodies, Bispecific - therapeutic use
antibody engineering
Antibody Specificity
Antigens, Neoplasm - immunology
armed antibodies
bispecific antibodies
Clinical Trials as Topic
Cytokines - chemistry
Cytokines - genetics
Cytokines - therapeutic use
Humans
Immune System - cytology
Immune System - immunology
Immune System - metabolism
immunocytokines
immunotherapy of cancer
Neoplasms - drug therapy
Neoplasms - immunology
Neoplasms - metabolism
Protein Binding
Protein Engineering
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The activation of the immune system for a selective removal of tumor cells represents an attractive strategy for the treatment of metastatic malignancies, which cannot be cured by existing methodologies. In this review, we examine the design and therapeutic potential of immunocytokines and bispecific antibodies, two classes of bifunctional products which can selectively activate the immune system at the tumor site. Certain protein engineering aspects, such as the choice of the antibody format, are common to both classes of therapeutic agents and can have a profound impact on tumor homing performance in vivo of individual products. However, immunocytokines and bispecific antibodies display different mechanisms of action. Future research activities will reveal whether an additive of even synergistic benefit can be obtained from the judicious combination of these two types of biopharmaceutical agents.
ISSN:0105-2896
1600-065X
DOI:10.1111/imr.12391